Cargando…

Tumor heterogeneity in muscle-invasive bladder cancer

Muscle-invasive bladder cancer (MIBC), a highly heterogeneous disease, shows genomic instability and a high mutation rate. Clinical outcomes are variable and responses to conventional chemotherapy differ among patients (due to inter-patient tumor heterogeneity and inter-tumor heterogeneity) and even...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ho Won, Kim, Wun-Jae, Choi, Woonyoung, Yun, Seok Joong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Article on Muscle-Invasive Bladder Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807360/ https://www.ncbi.nlm.nih.gov/pubmed/33457261 http://dx.doi.org/10.21037/tau.2020.03.13

Ejemplares similares

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

Role of PET/CT in muscle-invasive bladder cancer
por: Kim, Seok-ki
Publicado: (2020)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Update on bladder cancer molecular subtypes
por: Fong, Megan Hoi Yan, et al.
Publicado: (2020)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

The optimal management of variant histology in muscle invasive bladder cancer
por: Tiwari, Raj Vikesh, et al.
Publicado: (2020)

Is there an oncological benefit to extended lymphadenectomy for muscle-invasive bladder cancer?
por: Clinton, Timothy N., et al.
Publicado: (2020)

Partial cystectomy for muscle-invasive bladder cancer: a review of the literature
por: Peak, Taylor C., et al.
Publicado: (2020)

Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer
por: Sim, Ki Choon, et al.
Publicado: (2020)

Enhanced recovery after surgery of patients undergoing radical cystectomy for bladder cancer
por: Sung, Luck Hee, et al.
Publicado: (2020)

Review of the evidence for robotic-assisted robotic cystectomy and intra-corporeal urinary diversion in bladder cancer
por: Brodie, Andrew, et al.
Publicado: (2020)

Health-related quality of life after radical cystectomy
por: Choi, Hoon, et al.
Publicado: (2020)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial
por: Yu, Ge, et al.
Publicado: (2023)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data
por: Phull, Manraj, et al.
Publicado: (2023)

Fast skeletal muscle troponin activator CK‐2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction
por: Cheng, Arthur J., et al.
Publicado: (2019)

Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
por: Patil, Goutham, et al.
Publicado: (2022)

The determinants of transverse tubular volume in resting skeletal muscle
por: Sim, Jingwei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ngqvii7pdaj29e053s7m35v3qm